P103 - Efficacy and Safety of Sotagliflozin, a Dual Sodium-Glucose Cotransporter 1-2 Inhibitor, in Patients with Type 1Diabetes and Chronic Kidney Disease: A Post-Hoc Analysis of the inTandem Studies

People with type 1 diabetes (T1D), chronic kidney disease (CKD), and poor glycemic control are at high risk of kidney failure and cardiovascular events. Sodium glucose cotransporter (SGLT) inhibitors improve glycemic control in adults with T1D, but with an increased risk of diabetic ketoacidosis (DKA). This post-hoc analysis from inTandem 1, 2, & 3 evaluated the efficacy and safety of sotagliflozin (SOTA), a dual SGLT1 and SGLT2 inhibitor, in patients with T1D and CKD. Using patient-level data from the studies, the effects of SOTA (200 or 400 mg daily) were compared to placebo in a patient subgroup with T1D and CDK (eGFR <60 mL/min/1.73m2 and/or UACR >/= 30 mg/g). This poster displays the safety and efficacy results.